Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503549 | 1.00 | FFAR1 (0.42) | FFAR1SIRT6CYP2C8CYP2C9 | |
| SCHEMBL20444247 | 1.00 | FFAR1 (0.42) | FFAR1SIRT6CYP2C8CYP2C9 | |
| SCHEMBL20398724 | 1.00 | FFAR1 (0.42) | FFAR1SIRT6CYP2C8CYP2C9 | |
| SCHEMBL28998297 | 1.00 | FFAR1 (0.42) | FFAR1SIRT6CYP2C8CYP2C9 | |
| SCHEMBL28904056 | 1.00 | FFAR1 (0.42) | FFAR1SIRT6CYP2C8CYP2C9 | |
| SCHEMBL30239716 | 0.83 | FFAR1 (0.40) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL23543046 | 0.82 | FFAR1 (0.42) | FFAR1CYP2C8CYP2C9 | |
| SCHEMBL28960305 | 0.82 | FFAR1 (0.39) | FFAR1CYP2C8 | |
| SCHEMBL20398738 | 0.81 | FFAR1 (0.38) | FFAR1CYP2C8 | |
| SCHEMBL20398739 | 0.81 | FFAR1 (0.38) | FFAR1CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248929-B | Benzyl amino pyrazinyl cyclopropanecarboxylic acid, pharmaceutical composition and use thereof | 勃林格殷格翰国际有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110214135-B | Indanyl amino pyrazinyl cyclopropane carboxylic acid, pharmaceutical composition and application thereof | 勃林格殷格翰国际有限公司 | 2023-02-21 | — | — | CN | disclosed |